- Home
- GLOB vs SVRA Comparison
GLOB vs SVRA Comparison
Compare GLOB & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLOB | SVRA |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2015 | 2009 |
Fundamental Metrics
Financial Performance| Metric | GLOB | SVRA |
|---|---|---|
| Price | $46.60 | $4.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 9 |
| Target Price | ★ $52.00 | $11.06 |
| AVG Volume (30 Days) | 855.5K | ★ 2.4M |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.96 | $4,336.88 |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.56 | $3.86 |
| 52 Week High | $72.10 | $7.01 |
Technical Indicators
Market Signals| Indicator | GLOB | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 71.41 | 49.04 |
| Support Level | $41.92 | $4.73 |
| Resistance Level | $48.17 | $5.53 |
| Average True Range (ATR) | 2.08 | 0.29 |
| MACD | 0.54 | 0.05 |
| Stochastic Oscillator | 98.58 | 67.66 |
Price Performance
Historical ComparisonAbout GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).